Oncology Therapeutics Start-Up Oncologie Gets US$80M For Clinical-Stage Programs

China and US-based oncology therapeutics start-up Oncologie announced on Monday that it has closed a US$80 million series B round of financing led by Hong Kong-based life sciences-focused investment firm Nan Fung Life Sciences, and Pivotal BioVentures Partners China, a member of Nan Fung Life Sciences.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

China Expert network